To date there is no common or adequate therapeutic strategy for treatment of refractory schizophrenic patients. Increasing antipsychotics' doses in treatmentresistant schizophrenic patients is the most common intervention used by clinicians. Olanzapine is an atypical antipsychotic, which in a number of double-blind, placebocontrolled studies has been found to be more effective than haloperidol for the treatment of positive and negative symptoms of schizophrenia. During the last few years there have been several reports of successful results in prescribing olanzapine at dosages of more than 25 mg/day for treatment-resistant schizophrenic and schizoaffective patients. This report presents the results from the treatment of three resistant schizophrenic patients treated successfully with high dosages of olanzapine (35, 40, and 60 mg/day). None of the patients had any side effects, including abnormal laboratory levels and weight gain. The results and literature data suggest that in clinical practice some schizophrenic patients resistant to conventional neuroleptic treatment and not responding to olanzapine at recommended dosages as high as 20 mg/day may respond to higher dosages such as 40 or 60 mg/day, and these dosages are well tolerated. Further prospective clinical studies are needed.
The treatment of refractory or resistant psychosis continues to be a frequent and important problem in clinical practice. To date there is no common, adequate therapeutic strategy for treating these patients.
The clozapine treatment of resistant schizophrenic patients remains limited by the need for weekly blood monitoring for agranulocytosis. Moreover, side effects of clozapine such as sialorrhea and daytime sedation with relatively high incidence lead to poor compliance. Clozapine also induces dose-dependent seizures (1) .
Increasing antipsychotic doses in treatment-resistant schizophrenic patients is the most common intervention used by clinicians (2) . Despite some publications that show the absence of an advantage in higher doses in treatment-resistant patients over conventional doses, currently high doses of antipsychotics continue to be used to overcome resistance (3) .
Olanzapine is an atypical antipsychotic, which in a number of double-blind, placebo-controlled studies has been found to be more effective than haloperidol and risperidone for the treatment of positive and negative symptoms of schizophrenia. Furthermore, olanzapine has fewer extrapyramidal side effects (4) (5) (6) . The safety of olanzapine has been established in several trials at dosages of 5 to 20 mg/day (4, 6, 7) . However, there are many patients who responded partially to olanzapine in the recommended dose range and continued to have psychotic symptoms. During one open trial, researchers found that the more effective dosages for these patients were between 15 and 25 mg/day (8) . During the last few years there have been several successful reports regarding prescribing olanzapine at dosages of more than 25 mg/day for treatment of resistant schizophrenic and schizoaffective patients (9) (10) (11) (12) (13) (14) . There is an anecdotal case study that describes the treatment of a patient with Huntington's disease, and another in which a patient who had lethal catatonia is treated with high-dose olanzapine (15, 16) . Until now there have been few reports regarding the efficacy and side effects of olanzapine in higher doses. Here we present another three cases of successful treatment of resistant schizophrenic patients with high doses of olanzapine. The patients' clinical state was assessed with a rating from 0 to 6 points on the 18-item Brief Psychiatric Rating Scale (BPRS) (17) . Extrapyramidal symptoms were assessed with the Simpson-Angus Scale and the Barnes Akathisia Rating Scale (18, 19) .
CASE REPORTS

Patient 1
A 42-year-old woman with a 13-year history of paranoid schizophrenia characterized by social and occupational dysfunction, affect dysregulation, imperative hallucinations, and persecutory delusions failed to respond to haloperidol, trifluoperazine, perphenazine, zuclopenthixol, and thioridazine in doses in excess of 800 chlorpromazine equivalents daily alone and in combination with lithium, valproate, and carbamazepine. Furthermore, this treatment caused extrapyramidal symptoms. We could not begin clozapine treatment because of the refusal of the patient to undergo laboratory monitoring. The patient was started on risperidone and was raised to a dosage of 4 mg/day. Delusions improved, but severe tremor and akathisia prevented further dose increases (BPRS score, 51 points). Adding propranolol, diazepam, and trihexyphenidyl to her treatment did not influence the side effects. Risperidone was discontinued and olanzapine (10 mg/day) was added and raised to a dosage of 20 mg/day. For a period of 4 weeks, delusions were a little abated, but hallucinations continued to be present as well as disturbed social and occupational functioning (BPRS score, 47 points). Olanzapine was increased to 25 mg/day and after 3 weeks was increased to 30 mg/day because of the absence of further improvement (BPRS score, 46 points). During the next 3 weeks there were no side effects, but there was no amelioration of her mental state. Addition of valproate, as much as 1,200 mg/day, to the treatment (for possible augmentation) caused the disappearance of delusions and a stabilization of effect (BPRS score, 35 points). However, hallucinations continued and the patient was still unable to function. Valproate augmentation in a constant dose did not lead to further improvement of her mental state. Olanzapine was titrated to 60 mg/day during the next 3 months. A dose of 60 mg for the duration of 3 weeks resulted in maximal improvement: Hallucinations disappeared and the patient returned to normal functioning (BPRS score, 15 points). This high dose of olanzapine did not result in side effects. BPRS scores decreased by 70% from baseline. An attempt during 2 months to reduce the olanzapine dosage to 50 mg/day resulted in deterioration of her mental state: reappearance of "voices" and diminishing of social functioning. The olanzapine dosage was again increased to 60 mg/day. At the 7-month follow-up the patient continues to feel well, works as housewife, and has not experienced any relapses or required any medication changes. Her hematologic examination, including glucose and prolactin levels, did not reveal any pathologic findings. The patient's weight has remained stable.
Patient 2
A 22-year old man with a 5-year history of paranoid schizophrenia characterized by auditory hallucinations, persecutory delusions, and disruptive behavior failed to respond to conventional neuroleptics even in small doses (200-300 mg chlorpromazine equivalents) because of absence of response and severe extrapyramidal side effects. His parents refused to admit their son to a psychiatric hospital because of religious reasons and preferred private treatment. In Israel, according to the Ministry of Health's recommendations for starting clozapine treatment, a patient needs psychiatric hospitalization. Risperidone treatment in a dosage of 2 mg/day resulted in severe akathisia, and the patient categorically refused to continue treatment. Because of the lack of success with all the medication strategies suggested earlier, olanzapine was started at 10 mg daily without any side effects. However, the patient continued to report active symptomatology characterized by auditory hallucinations and delusions, and his behavior remained grossly disorganized (BPRS score, 48 points). His olanzapine dosage was increased to 15 mg/day and, after a week, was increased to 20 mg/day with minimal improvement. In 3 weeks he became calmer but without any change in psychotic symptoms. Olanzapine was increased to 25 mg daily, which resulted in a slight amelioration of symptoms (BPRS score, 45 points). For 4 weeks he took this olanzapine dose, but without any further clinical improvement, so olanzapine was increased to 30 mg/day. Twelve days later the patient had experienced only partial resolution of his symptoms (BPRS score, 37 points), but during the next month there was no additional amelioration of his mental state. Olanzapine was elevated again to 35 mg daily. No side effects were observed except mild somnolence. During the next 5 weeks his psychotic symptoms became less prominent and more controlled (BPRS score, 30 points), and he became more communicative and more in touch with reality. However he experienced episodic auditory imperative hallucinations that affected his behavior, and thus olanzapine was increased to 40 mg/day without any evidence of extrapyramidal side effects. At this point the patient's clinical condition improved dramatically (BPRS score, 12 points). Although hallucinations and delusions persisted, he was able to ignore them. He participated in some social activities. After the patient was released from the hospital he began meeting with friends and helping his mother with housework. After 3 months we reduced the olanzapine dosage to 35 mg/day. However, because of a deterioration in his mental state (outburst of petulance and alienation; BPRS score, 23 points), the olanzapine dosage was returned to 40 mg/day. The pa-tient returned to his previous good state. All laboratory data findings, including complete blood count, glucose, liver functions, and prolactin levels, were within normal limits and his weight was stable. His clinical improvement was supported by a 75% decrease in BPRS scores. The 1-year follow-up showed that the patient had maintained his level of improvement and his remission has been sustained.
Patient 3
A 29-year-old woman had a 9-year history of schizophrenia with social and occupational dysfunction. She had extensive exposure to different groups of conventional antipsychotic medications in various doses and combinations, without notable improvement. She remained overtly psychotic, agitated, and incoherent, and had persecutory delusions, delusions of references, control, thought insertion, and auditory hallucinations. Because of the severity of her psychiatric symptoms (BPRS score, 50 points), the patient was admitted to the hospital. She was started on clozapine and raised to a dosage of 250 mg/day, but severe hypotension, sedation, and hypersalivation prevented a further dose increase and led to noncompliance. Hallucinations and delusions continued to be present, and social and occupational function remained marginal. Clozapine treatment was discontinued, and risperidone was started and raised to a total dosage of 3 mg/day. The patient experienced mild clinical improvement (BPRS score, 46 points). However, because of a dystonic reaction and the appearance of severe akathisia that did not respond to propranolol and benzodiazepines, risperidone treatment was stopped. Olanzapine therapy was begun at 15 mg/day and was increased to 20 mg/day after 10 days. This regimen continued for 5 weeks, resulting in only mild clinical improvement (BPRS score, 41 points). Delusions and hallucinations continued to influence her behavior. The olanzapine dosage was raised to 25 mg/day. The patient experienced no adverse side effects, but there was no further improvement in her clinical state during the next 6 weeks. For this reason the olanzapine dosage was increased to 30 mg/day. Over a period of 2 weeks she became more coherent in her thoughts, but delusions and hallucinations persisted. Social and occupational functioning improved partially (BPRS score, 37 points). The next 5 weeks did not result in further improvement of her clinical state. At this point we elected to add valproate to her olanzapine treatment for possible augmentation. Her valproate dosage was increased gradually to 1,000 mg/day. She experienced substantial clinical improvement on this regimen, particularly with regard to hallucinations. However, she continued to exhibit persecutory delu-sions and delusions of reference (BPRS score, 31 points). This regimen continued for 7 weeks. Because the patient's clinical improvement was substantial but not optimal, we raised the olanzapine dosage to 35 mg/day. Within 3 weeks the patient reported that her delusions had abated (BPRS score, 22 points) and she was able to engage in her rehabilitation program. Other than mild tremor after increasing the olanzapine dosage to 35 mg/day, the patient experienced no adverse effects. Addition of vitamin B6 600 mg/day to her treatment resulted in the disappearance of tremor. She did not have any adverse hematologic effects. The patient's weight was stable. BPRS scores decreased by 56%. Seven weeks later the olanzapine dosage was reduced to 30 mg/day, with a resulting deterioration in her mental state. The patient reported a resurgence of persecutory delusions and appearance of hallucinations, and thus the olanzapine level was returned to the previous dosage of 35 mg/day. At 11 months of follow-up the patient has begun to work part-time and has not experienced any relapses nor required any medication changes.
DISCUSSION
Resistance, or nonresponsiveness to antipsychotic treatment, remains a marked problem in the clinical management of schizophrenic patients. Treatment resistance is in itself difficult to define, and the criteria remain controversial. Failure of at least two antipsychotics trials of adequate dose and duration of treatment are generally required to consider a patient treatment refractory (20, 21) , although some researchers believe that the length of an adequate drug trial is difficult to define (2) .
Olanzapine is an antipsychotic with a lower level of occupancy at the D 2 receptor than at the 5-hydroxytriptamine (5-HT) 2 receptor in dosages of as much as 20 mg/day (14, 22) . The efficacy of higher doses of olanzapine in the treatment of refractory schizophrenic patients may be a result of increased D 2 receptor occupancy that increased with dose. Some authors have found that there is a relationship between antipsychotic effect and the degree of D 2 receptor occupancy. They suggested that less than 60% D 2 occupancy might be insufficient to induce an antipsychotic response (23) .
A recent meta-analysis of the controlled studies of olanzapine showed that the dose-response curve is linear over dosages of 6.7, 11.5, and 16.4 mg/day. The authors did not reveal that the curve flattens out (24) .
Our experience with this study shows that some schizophrenic patients resistant to conventional neuroleptic treatment and not responding to olanzapine at recommended dosages as much as 20 mg/day may re-spond to higher dosages such as 40 or 60 mg/day, and these dosages are well tolerated. The olanzapine dose was increased each time in our patients after failure to respond after 3 to 7 weeks. This time is enough to see the treatment influence on clinical symptoms (25, 26) . The treatment of our three patients with high olanzapine dosages resulted in significant clinical improvement. This was supported by a reduction of 56%, 70%, and 75% in BPRS scores. The improvement seen in our patients is similar to that reported in some recently published papers (9) (10) (11) (12) (13) (14) . In two reports the patients were treated with as much as 60 mg/day of olanzapine, which did not produce side effects (10, 13) , and one case reported using an extraordinarily high dosage of 80 mg/day of olanzapine for at least 2 weeks without side effects except for mild tremor (11) . The other authors reported using olanzapine in dosages of as much as 40 mg/day. Most patients who are treated with high doses of olanzapine had an acceptable degree of overall tolerability. The extrapyramidal side effects were mild, and only some patients required concomitant psychotropic medications. These data confirm that adverse events associated with olanzapine treatment are rare (7) . Only in one trial in which the authors studied the long-term effects (40 weeks) on extrapyramidal symptoms, weight, liver toxicity, prolactin levels, and orthostatic vital signs of olanzapine high dosages (20-40 mg/day) in eight schizophrenic patients increase of weight in six patients, elevation of prolactin level in six patients, elevation of liver enzymes in four patients, and mild extrapyramidal symptoms in four patients were found (27) . The low rate of extrapyramidal symptoms at a high dose of olanzapine may be the result of a combination of relatively low striatal D 2 occupancy and higher 5-HT 2 receptor antagonism, and olanzapine built-in anticholinergic activity at higher doses (14, 28) .
These observations show that there are resistant schizophrenic patients who maybe treated with higher doses of olanzapine than those recommended normally without severe side effects; however, further prospective clinical studies are needed.
